75% reduction in incidence of meningitis B
(63 observed cases as compared with 253 expected cases; rate ratio: 0.25; 95% CI 0.19 to 0.36)
in a national immunisation programme in the United Kingdom1
Internet Explorer is no longer supported.
To provide you with the best possible experience, please switch to a supported browser e.g.
has been added to your basket
Significant impact in reducing the incidence of meningococcal B disease across countries, settings and target populations.1,2
No additional safety concerns in real world use beyond those identified in clinical trials in the UK and Canada.3,4
More than 50 million doses distributed worldwide.5
Video 5: Bexsero implementation in a National immunisation programme setting (UK)
Prescribing information (Great Britain and Northern Ireland)
Summary of product characteristics and patient information leaflet (Great Britain)
Summary of product characteristics and patient information leaflet (Northern Ireland)
Bexsero is a registered trademark of the GlaxoSmithKline group of companies
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline 0800 221 441
November 2022 | PM-GB-BEX-WCNT-200002 (V3.0)